970 reports of this reaction
4.3% of all RIFAMPIN reports
#3 most reported adverse reaction
DRUG INTERACTION is the #3 most commonly reported adverse reaction for RIFAMPIN, manufactured by Sanofi-Aventis U.S. LLC. There are 970 FDA adverse event reports linking RIFAMPIN to DRUG INTERACTION. This represents approximately 4.3% of all 22,393 adverse event reports for this drug.
Patients taking RIFAMPIN who experience drug interaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INTERACTION is moderately reported among RIFAMPIN users, representing a notable but not dominant share of adverse events.
In addition to drug interaction, the following adverse reactions have been reported for RIFAMPIN:
The following drugs have also been linked to drug interaction in FDA adverse event reports:
DRUG INTERACTION has been reported as an adverse event in 970 FDA reports for RIFAMPIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INTERACTION accounts for approximately 4.3% of all adverse event reports for RIFAMPIN, making it one of the most commonly reported side effect.
If you experience drug interaction while taking RIFAMPIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.